There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801
Recruiting
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥10% 2+/3+TC)
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/19/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Register for Updates
SELUTION SLR™ 014 In-stent Restenosis
NCT04280029
Recruiting
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR™ 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: HCA Centennial, Nashville, Tennessee
Conditions: Coronary Restenosis
Register for Updates
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: HER2-positive Advanced Solid Tumor
Register for Updates
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
NCT05387265
Recruiting
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute, LLC, Nashville, Tennessee
Conditions: Solid Tumors
Register for Updates
HEAL-LAA Clinical Trial
NCT05809596
Recruiting
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Ascension Saint Thomas, Nashville, Tennessee +2 locations
Conditions: Atrial Fibrillation, Bleeding, Stroke
Register for Updates
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997
Recruiting
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute (SCRI), Nashville, Tennessee
Conditions: Multiple Myeloma
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Tennesse Oncology, Nashville, Tennessee +1 locations
Conditions: Cancer
Register for Updates
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822
Recruiting
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Register for Updates
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
NCT05845710
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
06/18/2024
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Carotid Stenosis, Carotid Artery Diseases
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/18/2024
Locations: TriStar Skyline Medical Center, Nashville, Tennessee +1 locations
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864
Recruiting
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee +1 locations
Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Nashville, Tennessee
Conditions: Neoplasms
Register for Updates